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Although great advances have been made in stroke 
medicine in the past two decades, some questions 
about treatment in the acute phase of stroke remain. 
One such question is how to manage blood pressure? 
Blood pressure is often increased in acute ischaemic and 
haemorrhagic stroke,1 and ﬁ ndings from epidemiological 
studies suggest that high blood pressure in the acute 
phase is associated with poor outcome.1 The results of 
three large randomised clinical trials on blood pressure 
lowering in acute stroke—the Chinese Antihypertensive 
Trial in Acute Ischaemic Stroke2, the Intensive Blood 
Pressure Reduction in Acute Cerebral Haemorrhage 
Trial (INTERACT-2),3 and the Scandinavian Candesartan 
Acute Stroke Trial4—suggest that treatment should diﬀ er 
according to the type of stroke. 
In The Lancet Neurology, ﬁ ndings from two Articles 
provide new evidence for the importance of blood 
pressure in acute stroke. In one study, using data from the 
population-based Oxford Vascular Study, Urs Fischer and 
colleagues compared prestroke blood pressure values with 
blood pressure measured in the acute phase, and assessed 
whether this diﬀ ers in ischaemic versus haemorrhagic 
stroke.5 Patients with intracerebral haemorrhage had a 
steeper rise in blood pressure, higher blood pressure in 
the acute phase, and a more substantial fall within the 
ﬁ rst 24 h than did patients with ischaemic stroke.5
In the other study, Lisa Manning and colleagues did a 
post-hoc analysis of the INTERACT-2 trial—a randomised 
trial of intensive versus guideline blood pressure 
lowering in acute intracerebral haemorrhage—assessing 
the prognostic signiﬁ cance of blood pressure variability 
in the hyperacute phase (ﬁ rst 24 h) and the acute phase 
(days 2–7) after intracerebral haemorrhage.3,6 Episodic 
hypertension, single high systolic blood pressure, and 
variability of blood pressure in the hyperacute and the 
acute phases of an intracerebral haemorrhage were 
predictors of poor functional outcome.6
The ﬁ ndings from these two studies suggest that 
patients with ischaemic stroke caused by small-
vessel disease, and patients with deep or posterior 
haemorrhages, have higher blood pressure after stroke 
than patients with other ischemic stroke aetiologies 
or lobar haemorrhages, and when compared with 
recent pre-morbid measurements also have a steeper 
increase in blood pressure.5 These are important 
ﬁ ndings, indicating that the eﬀ ects of blood pressure 
should be diﬀ erentiated and managed, according to 
not only the type of stroke, but also to aetiology or 
lesion location. Such diﬀ erentiation should be a key 
area for future research.
For clinicians, the data presented in the papers 
suggest that we should closely monitor blood 
pressure in acute stroke. In patients with intracerebral 
haemorrhage, we should strive to maintain blood 
pressure at a constant level. However, the investigators 
showed an association between increasing blood 
pressure variability and greater intensity of blood 
pressure-lowering treat ment.6 An intriguing question 
therefore remains: if high variability in blood pressure 
worsens outcome, and greater intensity of treatment 
increases variability, should blood pressure really be 
lowered? If so, how much should it be lowered and 
what is the best method to achieve the target level?
In ischaemic stroke, blood pressure variability has 
been previously associated with poor outcome,7–9 and 
an association between high blood pressure and poor 
outcome has been shown in several populations.1,8 
However, there is no compelling evidence that lowering 
blood pressure is beneﬁ cial.2,4 Therefore, the prognostic 
signiﬁ cance of blood pressure variability in acute 
ischaemic stroke is an important topic for further 
investigation.
The Articles in The Lancet Neurology add to the 
evidence suggesting that blood pressure management 
in haemorrhagic stroke is important, hence treatment 
should diﬀ er according to type of stroke, and sudden 
changes and variability in blood pressure should be 
avoided. Findings from two large stroke trials with an 
expected blood pressure-lowering eﬀ ect are anticipated 
in 2014.10,11 Both trials have included patients with 
either ischaemic or haemorrhagic stroke and will 
add important evidence regarding blood pressure 
management in the acute phase.  
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Is screening of relatives for cerebral aneurysms justiﬁ ed?
A great deal of anxiety is caused within a family when a 
relative has an aneurysmal subarachnoid haemorrhage 
(aSAH), particularly if the aﬀ ected individual is young. 
If another member of the same family has had aSAH, 
the event provokes even greater anxiety. Inevitably, 
individuals start to question whether they could have 
an aneurysm and whether other family members will 
be aﬀ ected too. Individuals with at least two ﬁ rst-
degree relatives who have had aSAH have a signiﬁ cantly 
higher risk both of harbouring an aneurysm and of 
aSAH compared with the rest of the population1—in 
this large population-based study in Sweden, the odds 
ratio (OR) of aSAH was 2·1 if one first-degree relative 
had been affected and an OR of 51·0 with two affected 
first-degree relatives. Additionally, brain haemorrhages 
are also recorded at a younger age in individuals with a 
family history of aSAH than in those without.2,3
In The Lancet Neurology, Stijntje Bor and colleagues 
present ﬁ ndings from a 20-year period of screening for 
cerebral aneurysms in individuals with a family history of 
aSAH in the Netherlands.4 Individuals aged 16–18 years 
or older with at least two ﬁ rst-degree relatives who 
had had aSAH were oﬀ ered screening after counselling 
about possible side-eﬀ ects and modiﬁ able risk factors. 
Screening was mostly done with magnetic resonance 
angiography. After a negative screen, individuals were 
told to make contact after 5 years for repeated screening 
(although they were not actively called back).The 
authors report the yield of ﬁ rst and subsequent screens 
in a cohort of 458 individuals, who were followed 
up for up to 20 years. This cohort is unique, and the 
information provided by this series represents the best 
available information about screening for aSAH. 
Aneurysms were identiﬁ ed in 51 (11%) of the 
458 individuals at ﬁ rst screening and 21 (8%) of 
261 individuals at second screening.2 Overall, aneurysms 
